Acute (short term) treatment: 2 trials - Bussman - Crea
| verapamil vs control | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| reinfarction | no data | | confirmed myocardial infarction | NaN [NaN NaN] | p=1.00 | 0 | 54 | 1 | Bussman, | | cardiac death | no data | | All cause death | 0.86 [0.02 45.09] | p=1.00 | 0 | 54 | 1 | Bussman, |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| verapamil vs placebo | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| reinfarction | no data | | confirmed myocardial infarction | NaN [NaN NaN] | p=1.00 | 0 | 17 | 1 | Crea, | | cardiac death | no data | | All cause death | 0.23 [0.01 5.59] | p=1.00 | 0 | 17 | 1 | Crea, |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
Acute short term and post MI studies: 6 trials - Bussman - DAVIT I - Crea - DAVIT II - CRIS - Danish study
| verapamil vs control | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| reinfarction | no data | | confirmed myocardial infarction | NaN [NaN NaN] | p=1.00 | 0 | 54 | 1 | Bussman, | | cardiac death | no data | | All cause death | 0.86 [0.02 45.09] | p=1.00 | 0 | 54 | 1 | Bussman, |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| verapamil vs placebo | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| reinfarction | 0.81 [0.52 1.26] | p=1.00 | 0 | 1073 | 1 | CRIS, | | confirmed myocardial infarction | 0.99 [0.87 1.13] | p=1.00 | 0 | 3464 | 2 | Crea,Danish study, | | cardiac death | 0.83 [0.64 1.09] | p=1.00 | 0 | 2848 | 2 | DAVIT II,CRIS, | | All cause death | 0.94 [0.79 1.12] | p=1.00 | 0 | 6312 | 4 | Crea,DAVIT II,CRIS,Danish study, |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
Long term studies: 4 trials - DAVIT I - DAVIT II - CRIS - Danish study
| verapamil vs placebo | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| reinfarction | 0.81 [0.52 1.26] | p=1.00 | 0 | 1073 | 1 | CRIS, | | confirmed myocardial infarction | 0.99 [0.87 1.13] | p=1.00 | 0 | 3447 | 1 | Danish study, | | cardiac death | 0.83 [0.64 1.09] | p=1.00 | 0 | 2848 | 2 | DAVIT II,CRIS, | | All cause death | 0.94 [0.79 1.12] | p=1.00 | 0 | 6295 | 3 | DAVIT II,CRIS,Danish study, |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
All type of patient: 3 trials - VHAS - CONVINCE - INVEST (Pepine)
| verapamil vs atenolol | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| cardiovascular events | no data | | Cardiovascular death | no data | | stroke (fatal and non fatal) | no data | | Coronary event | no data | | Fatal MI | no data | | Non fatal MI | 0.99 [0.79 1.24] | p=1.00 | 0 | 22576 | 1 | INVEST (Pepine), | | Heart failure | no data | | Diabetes onset | no data | | Angina | no data | | Peripheral arterial disease | no data | | End stage renal disease | no data | | Revascularization | no data | | All cause death | 0.98 [0.89 1.08] | p=1.00 | 0 | 22576 | 1 | INVEST (Pepine), | | Fatal stroke | no data | | Non fatal stroke | 0.89 [0.70 1.13] | p=1.00 | 0 | 22576 | 1 | INVEST (Pepine), |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| verapamil vs chlorthalidone | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| cardiovascular events | 1.07 [0.51 2.24] | p=1.00 | 0 | 1414 | 1 | VHAS, | | Cardiovascular death | 1.25 [0.33 4.67] | p=1.00 | 0 | 1414 | 1 | VHAS, | | stroke (fatal and non fatal) | 1.25 [0.33 4.67] | p=1.00 | 0 | 1414 | 1 | VHAS, | | Coronary event | 0.90 [0.36 2.23] | p=1.00 | 0 | 1414 | 1 | VHAS, | | Fatal MI | 0.75 [0.17 3.36] | p=1.00 | 0 | 1414 | 1 | VHAS, | | Non fatal MI | 1.00 [0.29 3.47] | p=1.00 | 0 | 1414 | 1 | VHAS, | | Heart failure | 3.00 [0.12 73.77] | p=1.00 | 0 | 1414 | 1 | VHAS, | | Diabetes onset | no data | | Angina | no data | | Peripheral arterial disease | no data | | End stage renal disease | no data | | Revascularization | no data | | All cause death | 1.25 [0.33 4.67] | p=1.00 | 0 | 1414 | 1 | VHAS, | | Fatal stroke | 7.00 [0.36 135.77] | p=1.00 | 0 | 1414 | 1 | VHAS, | | Non fatal stroke | 0.75 [0.17 3.36] | p=1.00 | 0 | 1414 | 1 | VHAS, |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| verapamil vs diuretic or beta-blocker | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| cardiovascular events | 1.01 [0.87 1.17] | p=1.00 | 0 | 16602 | 1 | CONVINCE, | | Cardiovascular death | 1.08 [0.86 1.36] | p=1.00 | 0 | 16602 | 1 | CONVINCE, | | stroke (fatal and non fatal) | 0.81 [0.65 1.02] | p=1.00 | 0 | 16602 | 1 | CONVINCE, | | Coronary event | 0.81 [0.65 1.02] | p=1.00 | 0 | 16602 | 1 | CONVINCE, | | Fatal MI | no data | | Non fatal MI | no data | | Heart failure | no data | | Diabetes onset | no data | | Angina | no data | | Peripheral arterial disease | no data | | End stage renal disease | no data | | Revascularization | no data | | All cause death | 1.07 [0.92 1.25] | p=1.00 | 0 | 16602 | 1 | CONVINCE, | | Fatal stroke | no data | | Non fatal stroke | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
Patients with additional risk factor: 2 trials - CONVINCE - INVEST (Pepine)
| verapamil vs atenolol | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| cardiovascular events | no data | | Cardiovascular death | no data | | stroke (fatal and non fatal) | no data | | Coronary event | no data | | Fatal MI | no data | | Non fatal MI | 0.99 [0.79 1.24] | p=1.00 | 0 | 22576 | 1 | INVEST (Pepine), | | Heart failure | no data | | Diabetes onset | no data | | Angina | no data | | Peripheral arterial disease | no data | | End stage renal disease | no data | | Revascularization | no data | | All cause death | 0.98 [0.89 1.08] | p=1.00 | 0 | 22576 | 1 | INVEST (Pepine), | | Fatal stroke | no data | | Non fatal stroke | 0.89 [0.70 1.13] | p=1.00 | 0 | 22576 | 1 | INVEST (Pepine), |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| verapamil vs diuretic or beta-blocker | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| cardiovascular events | 1.01 [0.87 1.17] | p=1.00 | 0 | 16602 | 1 | CONVINCE, | | Cardiovascular death | 1.08 [0.86 1.36] | p=1.00 | 0 | 16602 | 1 | CONVINCE, | | stroke (fatal and non fatal) | 0.81 [0.65 1.02] | p=1.00 | 0 | 16602 | 1 | CONVINCE, | | Coronary event | 0.81 [0.65 1.02] | p=1.00 | 0 | 16602 | 1 | CONVINCE, | | Fatal MI | no data | | Non fatal MI | no data | | Heart failure | no data | | Diabetes onset | no data | | Angina | no data | | Peripheral arterial disease | no data | | End stage renal disease | no data | | Revascularization | no data | | All cause death | 1.07 [0.92 1.25] | p=1.00 | 0 | 16602 | 1 | CONVINCE, | | Fatal stroke | no data | | Non fatal stroke | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
Uncomplicated hypertension: 1 trials - VHAS
| verapamil vs chlorthalidone | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| cardiovascular events | 1.07 [0.51 2.24] | p=1.00 | 0 | 1414 | 1 | VHAS, | | Cardiovascular death | 1.25 [0.33 4.67] | p=1.00 | 0 | 1414 | 1 | VHAS, | | stroke (fatal and non fatal) | 1.25 [0.33 4.67] | p=1.00 | 0 | 1414 | 1 | VHAS, | | Coronary event | 0.90 [0.36 2.23] | p=1.00 | 0 | 1414 | 1 | VHAS, | | Fatal MI | 0.75 [0.17 3.36] | p=1.00 | 0 | 1414 | 1 | VHAS, | | Non fatal MI | 1.00 [0.29 3.47] | p=1.00 | 0 | 1414 | 1 | VHAS, | | Heart failure | 3.00 [0.12 73.77] | p=1.00 | 0 | 1414 | 1 | VHAS, | | Diabetes onset | no data | | Angina | no data | | Peripheral arterial disease | no data | | End stage renal disease | no data | | Revascularization | no data | | All cause death | 1.25 [0.33 4.67] | p=1.00 | 0 | 1414 | 1 | VHAS, | | Fatal stroke | 7.00 [0.36 135.77] | p=1.00 | 0 | 1414 | 1 | VHAS, | | Non fatal stroke | 0.75 [0.17 3.36] | p=1.00 | 0 | 1414 | 1 | VHAS, |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
All type of patients: 1 trials - Hoberg
| verapamil vs placebo | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
All type of patients: 4 trials - DAVIT I - DAVIT II - CRIS - Danish study
| verapamil vs placebo | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| reinfarction | 0.81 [0.52 1.26] | p=1.00 | 0 | 1073 | 1 | CRIS, | | confirmed myocardial infarction | 0.99 [0.87 1.13] | p=1.00 | 0 | 3447 | 1 | Danish study, | | cardiac death | 0.83 [0.64 1.09] | p=1.00 | 0 | 2848 | 2 | DAVIT II,CRIS, | | All cause death | 0.94 [0.79 1.12] | p=1.00 | 0 | 6295 | 3 | DAVIT II,CRIS,Danish study, |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
